SM 04690

Drug Profile

SM 04690

Alternative Names: SM-04690

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Samumed
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Clinical Phase Unknown Intervertebral disc degeneration

Most Recent Events

  • 15 Nov 2016 Samumed files an IND application with the FDA in USA for Intervertebral disc degeneration
  • 15 Nov 2016 Samumed plans a phase I trial for Intervertebral disc degeneration in USA
  • 01 Nov 2016 Clinical trials in Intervertebral disc degeneration in USA (Parenteral) (Samumed pipeline,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top